Aevi Genomic Medicine (GNMX) Given Media Sentiment Rating of 0.02

News stories about Aevi Genomic Medicine (NASDAQ:GNMX) have trended somewhat positive this week, according to Accern Sentiment Analysis. The research firm ranks the sentiment of media coverage by monitoring more than twenty million news and blog sources. Accern ranks coverage of public companies on a scale of negative one to one, with scores nearest to one being the most favorable. Aevi Genomic Medicine earned a daily sentiment score of 0.02 on Accern’s scale. Accern also assigned news headlines about the biotechnology company an impact score of 45.9201639720822 out of 100, meaning that recent media coverage is somewhat unlikely to have an effect on the company’s share price in the next few days.

Aevi Genomic Medicine (GNMX) traded down $0.01 during trading hours on Tuesday, hitting $1.52. The company had a trading volume of 69,300 shares, compared to its average volume of 481,626. Aevi Genomic Medicine has a 12 month low of $0.98 and a 12 month high of $6.89.

Aevi Genomic Medicine (NASDAQ:GNMX) last announced its earnings results on Thursday, November 2nd. The biotechnology company reported ($0.23) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.22) by ($0.01). During the same period last year, the company posted ($0.29) earnings per share. research analysts anticipate that Aevi Genomic Medicine will post -0.86 earnings per share for the current year.

A number of analysts recently issued reports on GNMX shares. Jefferies Group LLC reiterated a “hold” rating and set a $1.50 price objective on shares of Aevi Genomic Medicine in a research note on Monday, August 7th. Needham & Company LLC decreased their price objective on Aevi Genomic Medicine from $9.00 to $7.00 and set a “buy” rating on the stock in a research note on Wednesday, August 16th.

COPYRIGHT VIOLATION NOTICE: “Aevi Genomic Medicine (GNMX) Given Media Sentiment Rating of 0.02” was reported by Transcript Daily and is owned by of Transcript Daily. If you are reading this news story on another domain, it was copied illegally and republished in violation of U.S. & international copyright & trademark law. The original version of this news story can be read at

In other Aevi Genomic Medicine news, insider Garry Arthur Neil bought 75,000 shares of the firm’s stock in a transaction on Tuesday, October 17th. The shares were acquired at an average cost of $1.26 per share, for a total transaction of $94,500.00. Following the purchase, the insider now directly owns 114,774 shares of the company’s stock, valued at $144,615.24. The acquisition was disclosed in a filing with the SEC, which is available through this hyperlink. Also, Director Sol J. Barer bought 421,032 shares of the firm’s stock in a transaction on Tuesday, October 17th. The stock was acquired at an average price of $1.26 per share, for a total transaction of $530,500.32. Following the completion of the purchase, the director now directly owns 1,028,032 shares in the company, valued at $1,295,320.32. The disclosure for this purchase can be found here. Insiders acquired a total of 625,440 shares of company stock worth $787,433 over the last 90 days. Corporate insiders own 15.20% of the company’s stock.

About Aevi Genomic Medicine

Aevi Genomic Medicine, Inc, a clinical stage biopharmaceutical company, researches and develops novel therapies for pediatric onset and life-altering diseases in the United States. Its lead product candidates include AEVI-001, a glutamatergic neuromodulator, which is in Phase II/III SAGA trial for a genetically-defined subset of adolescent attention deficit hyperactivity disorder patients with specific mutations in their metabotropic glutamate receptor gene network; and AEVI-002, an anti-light monoclonal antibody that is in Phase I clinical trial for use in severe pediatric onset crohn’s disease.

Insider Buying and Selling by Quarter for Aevi Genomic Medicine (NASDAQ:GNMX)

Receive News & Ratings for Aevi Genomic Medicine Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aevi Genomic Medicine Inc. and related companies with's FREE daily email newsletter.

Leave a Reply